Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France)

Abstract

The online version of this article has a Supplementary Appendix. BackgroundEpidemiological data on myeloid malignancies are very rare in the literature due to a lack of registration by cancer registries until 2000. The Registry of Hematologic Malignancies of the Côte d'Or Department in France has, however, steadfastly registered data on cases occurring in the Department since 1980, resulting, to date, in a database of over 5,000 cases classified according to the ICD-O-3 classification, following the most recent World Health Organization classification criteria. Design and MethodsTwenty-five years of data on myeloid malignancies, including acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic/myeloproliferative syndromes were analyzed. World population standardized incidence rates were calculated as were as observed and relative survival. ResultsIncidence rates per 100,000 inhabitants/year were 2.5 for acute myeloid leukemia, 1.3 for myelodysplastic syndromes, 3.2 for myeloproliferative neoplasms and 0.6 for myelodysplastic/myeloproliferative syndromes. It was found that the incidence rate of myelodysplastic syndromes increased significantly over the period. The median overall survival is 8.9 months for patients with acute myeloid leukemia, 33.8 months for patients with myelodysplastic syndromes, 91.7 months for those with myeloproliferative neoplasms and 26.6 months for patients with myelodysplastic/myeloproliferative syndromes. Observed and relative 20-year survival rates are, respectively, 12% and 13% in acute myeloid leukemia, 2% and 6% in myelodysplastic syndromes and 20% and 34% in myeloproliferative neoplasms. ConclusionsThese population-based data on myeloid malignancies are the first data collected over such a long period and provide interesting information for clinicians and public health authorities, particularly given the paucity of other long-term, population-based data from cancer registries.Key words: myeloid malignancies, incidence, survival, cancer registry. (Burgundy, France). Haematologica 2011;96(1):55-61. doi:10.3324/haematol.2010 Citation: Maynadié M,* Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F, Favre B Caillot D, Petrella T, Flesch M, and Carli P-M. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Côte d'Or

Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain

“…The incidence rate of AML in the province of Girona was similar to that reported in France, south-east England and Sardinia. 6,8,11 Nevertheless, the proportion of AML with cytogenetic abnormalities in our cohort was lower than in France and the UK. 8,12 This is probably because karyotype tests were made outside the province of Girona and information was not always available for older cases.…”

“…ilar to results reported from France, the UK and the US. 8,12,15 According to our predictions, 7,551 new cases of MMs will be diagnosed in Spain for the year 2013, of which 1,772 cases will be AML, 2,647 MDS, 2,744 MPN and 388 MDS/MPN. These results are of interest for clinicians and those involved in public health in order to evaluate the cost of new treatments for these pathologies.…”

“…They used positive criteria such as karyotype abnormalities or evolution to a more aggressive type to register cases of refractory anemia in order to avoid the inclusion of false cases. 8 The lower incidence of MDS in the US may be due to the underreporting of cases.…”

Myelofibrosis patients in Belgium: disease characteristics

“…2,3 The median overall survival for MF patients is 4 to 6 years from time of diagnosis. 4,5 The major causes of death include progressive bone marrow failure, infections and transformation to acute leukemia. 6 Published data on the incidence and prevalence of MF in Europe are limited.…”

“…6 Published data on the incidence and prevalence of MF in Europe are limited. 5,[7][8][9][10] Estimates of the annual incidence of MF in Europe range between 0.3 and 0.6 cases per 100 000 persons. 5,[7][8][9] MF is most commonly diagnosed in patients over the age of 50, 7,9 and appears to be more frequent in men.…”